benecel™ ph dc hpmc

chemistry: cellulosics

SDS Link >

To meet growing demand for Benecel™ PH DC hypromellose (hpmc), a patented, surface-modified, co-processed pharmaceutical excipient that provides improved performance in direct compression and continuous manufacturing controlled-release applications, Ashland has invested in additional, relocated manufacturing capacity.

While simultaneously reducing lead time to meet demand and improving delivery continuity, the investment also enhances Ashland’s production capacity for ancillary custom molecular weight Benecel™ hpmc pharmaceutical excipients. Customization of Benecel™ grades helps customers circumvent batch blending processes that can result in unpredictable release rate variability for active pharmaceutical ingredients (APIs).


  • tablet binding
  • modified release
  • continuous manufacturing

key features and benefits

Used for modified release and tablet binding, Benecel™ PH DC hpmc and related customizable forms deliver multiple benefits:

  • improved powder flow
  • increased predictability and reproducibility of drug release profiles
  • identical, stable dissolution profiles compared with “CR” grades
  • improved content uniformity

grades available

Read More >

additional content coming soon

additional content coming soon

additional content coming soon

additional content coming soon

request a sample link2.jpg
contact us link.jpg